BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Eight studies assessed VE of primary series or first booster dose vaccination separately for at least two different Omicron subvariants (six assessed VE of both primary series and booster dose vaccination and two assessed VE of a booster dose only).
“Eight studies assessed VE of primary series or first booster dose vaccination separately for at least two different Omicron subvariants (six assessed VE of both primary series and booster dose vaccination and two assessed VE of a booster dose only, Tables 1 and 2) [21,24-26,28-33].”
From Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) · cites this paper as [32]
Split into 2 atoms — 1 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredOf three studies assessing VE against infection/symptomatic disease during both BA.2 and BA.4/BA.5 periods, all showed similar VE estimates or estimates with overlapping 95 % confidence intervals against both subvariants.
“Of three studies assessing VE against infection/symptomatic disease during both BA.2 and BA.4/BA.5 periods, all showed similar VE estimates or estimates with overlapping 95 % confidence intervals against both subvariants [25,26,31-33].”
From Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) · cites this paper as [32]
The methods and VE table (page not specified in our copy) report BNT162b2 effectiveness against BA.4/5, including outpatient encounters. This paper does not provide BA.2 VE estimates for the same study or compare BA.2 and BA.4/5 estimates or their 95% confidence intervals; it points to a separate previous BA.2 analysis. (LLM, conf=0.85)
Experimental — accuracy not yet measuredOf two studies reporting primary series VE against hospitalization/severe disease against BA.1, BA.2, and BA.4/5, one reported lower VE against BA.2 and BA.4/5 than BA.1, while the other showed no statistically significant differences.
“Of two studies reporting primary series VE against hospitalization/severe disease against BA.1, BA.2, and BA.4/5, one reported lower VE against BA.2 and BA.4/5 than BA.1, while the other showed no statistically significant differences [25,26,31,32].”
From Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) · cites this paper as [32]
The results and adjusted-effectiveness table report two-dose vaccine effectiveness against BA.4/5-related hospitalisation. This paper does not report a primary-series hospitalisation comparison across BA.1, BA.2, and BA.4/5, or test whether differences between those variants were statistically significant. The copy provides no page number for these passages. (LLM, conf=0.87)
Experimental — accuracy not yet measuredAmong three studies comparing VE against BA.1 and BA.4/5, two showed a lower VE against BA.4/5.
“Among three studies comparing VE against BA.1 and BA.4/5, two showed a lower VE against BA.4/5 [24-26,31,32].”
From Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) · cites this paper as [32]
The study description and effectiveness table report BNT162b2 effectiveness against BA.4/5, but provide no BA.1 effectiveness estimates for comparison. The introduction mentions lower neutralisation of BA.4/5 than BA.1, which is not a comparison of vaccine effectiveness. A search for a BA.1-versus-BA.4/5 effectiveness comparison found none in our copy; it also does not establish the claim's count of three studies, two with lower effectiveness. (LLM, conf=0.76)
Experimental — accuracy not yet measuredIn the one VE study that provided data on prior infection, the percentage of people infected between BA.1/2 and BA.4/5 periods increased more among unvaccinated persons (from 15% to 39%) than among vaccinated persons (from 14% to 25%).
“In the one VE study that did provide data on prior infection, the percentage of people infected between the BA.1/2 and BA.4/5 periods increased more among unvaccinated persons (from 15 % to 39 %) than among vaccinated persons (from 14 % to 25 %) [31,32].”
From Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) · cites this paper as [32]
The paper’s discussion says natural immunity could not be sufficiently measured and raises undocumented BA.1/BA.2 infections as a possible source of bias. Searches for prior-infection data by vaccination status and the claimed percentages found no passage reporting a 15% to 39% increase among unvaccinated people or a 14% to 25% increase among vaccinated people. (LLM, conf=0.74)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney, K., Makatini, Z., Moyo, S., Amoako, D. G., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01911-2 · Cited by 707 · see citing works
Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
Qu, P., Faraone, J. N., Evans, J. P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206725 · Cited by 161 · see citing works
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4150500 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
1 of the 4 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [3]Our World in Data SARS-CoV-2 sequences by Variant, Mar 1, 2021 2022 Oxford Martin School University of Oxford https://ourworldindata.org/grapher/covid-variants-bar?time=earliest&country=CAN~BWA~ESP~ZAF~AUS~GBR~USA~DEU~ITA~BEL~FRA
Cited by
Sorted by citations
Tseng, H. F., Ackerson, B. K., Bruxvoort, K. J., Sy, L. S., Tubert, J. E., Lee, G. S., Ku, J. H., Florea, A., Luo, Y., Qiu, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35815-7 · Cited by 105 · see citing works
Self-citationTracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 76 · see citing works
Pather, S., Madhi, S. A., Cowling, B. J., Moss, P. A. H., Kamil, J. P., Ciesek, S., Muik, A., & Türeci, Ö. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130539 · Cited by 59 · see citing works
Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19
Tartof, S. Y., Slezak, J. M., Frankland, T. B., Puzniak, L., Hong, V. X., Ackerson, B. K., Stern, J. A., Zamparo, J. M., Simmons, S. R., Jódar, L., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.1640 · Cited by 45 · see citing works
Self-citationCOVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Nham, E., Song, J. Y., Noh, J. Y., Cheong, H. J., & Kim, W. J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e351 · Cited by 41 · see citing works
Feikin, D. R., Higdon, M. M., Andrews, N., Collie, S., Deloria Knoll, M., Kwong, J. C., Link-Gelles, R., Pilishvili, T., & Patel, M. K. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.020 · Cited by 36 · see citing works
“Study (Country, Vaccine) Outcome Age group (years) Time interval since last dose used for VE estimate Median of time interval since last dose (days) 2 dose VE (95 % CI) BA.1 BA.2* BA.1/BA.2* BA.4/BA.5 Chemaitelly et al (Qatar, BNT162b2) [29] Symptomatic disease All ages 1–3 m 46.6 (33.4, 57.2) 51.7 (43.2, 58.9) 4–6 m…”
InfluentialOmicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
Chavda, V. P., Balar, P. C., Vaghela, D. A., Solanki, H., Vaishnav, A., Hala, V., & Vora, L. K. (2023) · Vaccines · doi:10.3390/vaccines11010160 · Cited by 37 · see citing works
Song, S., Madewell, Z. J., Liu, M., Longini, I. M., & Yang, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1195908 · Cited by 34 · see citing works
Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages
Tartof, S. Y., Slezak, J. M., Puzniak, L., Frankland, T. B., Ackerson, B. K., Jódar, L., & McLaughlin, J. M. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae370 · Cited by 30 · see citing works
Self-citationThe real-time infection hospitalisation and fatality risk across the COVID-19 pandemic in England
Ward, T., Fyles, M., Glaser, A., Paton, R. S., Ferguson, W., & Overton, C. E. (2024) · Nature Communications · doi:10.1038/s41467-024-47199-3 · Cited by 26 · see citing works
Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Fafard, J., Gilca, R., Talbot, D. C., Ouakki, M., Febriani, Y., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00099-5 · Cited by 24 · see citing works
McGrath, L. J., Malhotra, D., Miles, A. C., Welch, V. L. L., Fusco, M. D., Surinach, A., Barthel, A. B., Alfred, T., Jódar, L., & McLaughlin, J. M. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.42151 · Cited by 23 · see citing works
Self-citationBreznik, J. A., Rahim, A., Zhang, A., Ang, J. C., Stacey, H. D., Bhakta, H., Clare, R., Liu, L., Kennedy, A. E., Hagerman, M., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102148 · Cited by 21 · see citing works
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Usdan, L. S., Patel, S., Rodriguez, H., Xu, X., Lee, D.-Y., Finn, D., Wyper, H., Lowry, F. S., Mensa, F., Lu, C., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad718 · Cited by 20 · see citing works
Bennett, C., Woo, W., Bloch, M., Cheung, K., Griffin, P. M., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., Neville, A. M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00077-x · Cited by 19 · see citing works
Rudolph, A. E., Khan, F. L., Shah, A., Singh, T. G., Wiemken, T. L., Puzniak, L., Jódar, L., & McLaughlin, J. M. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad474 · Cited by 18 · see citing works
Self-citationSafety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Hannawi, S., Eldin, L. S., Abuquta, A., Alamadi, A., Mahmoud, S., Hassan, A., Xu, S., Li, J., Liu, D., Baidoo, A. A. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39766-x · Cited by 16 · see citing works
Stauft, C. B., Selvaraj, P., D’Agnillo, F., Meseda, C. A., Liu, S., Pedro, C. L., Sangare, K., Lien, C. Z., Weir, J. P., Starost, M. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39090-4 · Cited by 16 · see citing works
Plumb, I. D., Hagen, M. B., Wiegand, R. E., Dumyati, G. K., Myers, C., Harland, K. K., Krishnadasan, A., James-Gist, J., Abedi, G. R., Fleming-Dutra, K. E., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.072 · Cited by 16 · see citing works
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity
Roederer, A. L., Cao, Y., Denis, K. S., Sheehan, M. L., Li, C. J., Lam, E. C., Gregory, D. J., Poznansky, M. C., Iafrate, A. J., Canaday, D. H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101850 · Cited by 17 · see citing works
BNT162b2 XBB1.5-adapted Vaccine and COVID-19 Hospital Admissions and Ambulatory Visits in US AdultsPreprint
Tartof, S. Y., Slezak, J. M., Frankland, T. B., Puzniak, L., Hong, V. X., Ackerson, B. K., Stern, J. A., Simmons, S. R., Jódar, L., & McLaughlin, J. M. (2023) · medRxiv · doi:10.1101/2023.12.24.23300512 · Cited by 18 · see citing works
Self-citationShoaib, S., Ansari, M. A., Kandasamy, G., Vasudevan, R., Hani, U., Chauhan, W., Alhumaidi, M. S., Altammar, K. A., Azmi, S., Ahmad, W., et al. (2023) · Molecules · doi:10.3390/molecules28020795 · Cited by 15 · see citing works
Fusco, M. D., Marczell, K., Thoburn, E., Wiemken, T. L., Yang, J., & Yarnoff, B. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2193067 · Cited by 15 · see citing works
Mateo‐Urdiales, A., Sacco, C., Petrone, D., Bella, A., Riccardo, F., Manso, M. D., Bressi, M., Siddu, A., Brusaferro, S., Palamara, A. T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36854 · Cited by 13 · see citing works
Arashiro, T., Arima, Y., Kuramochi, J., Muraoka, H., Sato, A., Chubachi, K., Oba, K., Yanai, A., Arioka, H., Uehara, Y., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.021 · Cited by 13 · see citing works
Bennett, C., Rivers, E. J., Woo, W., Bloch, M., Cheung, K., Griffin, P. M., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad508 · Cited by 13 · see citing works
Feldstein, L. R., Ruffin, J. D., Wiegand, R. E., Borkowf, C. B., James-Gist, J., Babu, T. M., Hagen, M. B., Chappell, J. D., Chu, H. Y., Englund, J. A., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf007 · Cited by 13 · see citing works
Sivasankar, C., Hewawaduge, C., & Lee, J. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.015 · Cited by 13 · see citing works
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
Lewnard, J. A., Hong, V. X., Kim, J. S., Shaw, S. F., Lewin, B. J., Takhar, H. S., Lipsitch, M., & Tartof, S. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39567-2 · Cited by 11 · see citing works
Self-citationKislaya, I., Sentís, A., Starrfelt, J., Nunes, B., Martínez‐Baz, I., Nielsen, K. F., Alkerwi, A., Braeye, T., Fontán‐Vela, M., Bacci, S., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13195 · Cited by 12 · see citing works
He, Q., Sun, S., Chen, X., Hu, Z., Zhang, Y., Peng, H., Fu, Y., Yang, J., & Chen, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010146 · Cited by 11 · see citing works
Beck, E. C., Georgieva, M. V., Wang, W., Gómez-Liévano, A., Wang, H., Gao, Y., Kopel, H., Bausch-Jurken, M. T., Patterson‐Lomba, O., Mu, F., et al. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2466726 · Cited by 8 · see citing works
Milito, C., Firinu, D., Bez, P., Villa, A., Punziano, A., Lagnese, G., Costanzo, G. A. M. L., van Leeuwen, L. P. M., Piazza, B., Deiana, C. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093385 · Cited by 9 · see citing works
Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection
Qiao, R., Li, J., Gong, J., Shao, Y., Yu, J., Chen, Y., Lu, Y., Yang, L., Lin, L., Hu, Z., et al. (2025) · Vaccines · doi:10.3390/vaccines13060635 · Cited by 7 · see citing works
Thakkar, K. B., Spinardi, J., Kyaw, M. H., Yang, J., Mendoza, C. F., Ozbilgili, E., Dodd, J., Yarnoff, B., & Punrin, S. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2265460 · Cited by 7 · see citing works
Wolff, A. S. B., Hansen, L., Grytaas, M. A., Oftedal, B. E., Breivik, L., Zhou, F., Hufthammer, K. O., Sjøgren, T., Olofsson, J. S., Trieu, M.-C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107084 · Cited by 7 · see citing works
Marron, L., Mateo‐Urdiales, A., O’Donnell, J., Robinson, E., & Domegan, L. M. (2024) · Eurosurveillance · doi:10.2807/1560-7917.es.2024.29.28.2300697 · Cited by 9 · see citing works
Considerations in Understanding Vaccine Effectiveness
Lau, C. S., & Aw, T. C. (2022) · Vaccines · doi:10.3390/vaccines11010020 · Cited by 6 · see citing works
Martin, B. M., Restrepo, A. C., Mayfield, H. J., Paulino, C. T., Aubin, M. D. S., Duke, W., Jarolı́m, P., Gutiérrez, E. Z., Skewes-Ramm, R., Dumas, D., et al. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed8110493 · Cited by 5 · see citing works
The BCG vaccine and SARS-CoV-2: Could there be a beneficial relationship?
Peña-Bates, C. A., Lascuraín, R., Ortiz-Navarrete, V. F., & Chávez‐Galán, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38085 · Cited by 5 · see citing works
Smith, D. S., Postma, M. J., Fisman, D. N., & Mould-Quevedo, J. F. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126879 · Cited by 5 · see citing works
Thakkar, K. B., Spinardi, J., Kyaw, M. H., Yang, J., Mendoza, C. F., Ozbilgili, E., Taysi, B. N., Dodd, J., Yarnoff, B., & Oh, H. M. L. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2290931 · Cited by 4 · see citing works
Keane, A. E., Tippett, A., Taylor, E. G., Reese, O., Moscote‐Salazar, L. R., Castro, K. D., Choi, C., Ciric, C. R., Taylor, M., Mitchell, A., et al. (2024) · Vaccines · doi:10.3390/vaccines12060657 · Cited by 4 · see citing works
Self-citationCorrelation of SARS-CoV-2 Neutralization with Antibody Levels in Vaccinated Individuals
Chowdhury, S. H., Riley, S., Mikolajczyk, R., Smith, L. N., Suresh, L., & Jacobs, A. (2023) · Viruses · doi:10.3390/v15030793 · Cited by 3 · see citing works
Trombetta, C. M., Marchi, S., Leonardi, M., Coppola, C., Benincasa, L., Marotta, M., Buonvino, N., Maes, P., Stufano, A., Pontrelli, D., et al. (2023) · Acta Tropica · doi:10.1016/j.actatropica.2023.107042 · Cited by 3 · see citing works
Meurisse, M., Catteau, L., van Loenhout, J. A. F., Braeye, T., Mot, L. D., Serrien, B., Blot, K. Y., Cauët, É., Oyen, H. J. V., Cuypers, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11020378 · Cited by 3 · see citing works
Vicenti, I., Basso, M., Pirola, N., Bragato, B., Rossi, M. C., Giobbia, M., Pascoli, S., Vinci, A., Caputo, S., Varasi, I., et al. (2023) · Vaccines · doi:10.3390/vaccines11040871 · Cited by 3 · see citing works
Thakkar, K. B., Spinardi, J., Kyaw, M. H., Yang, J., Mendoza, C. F., Dass, M., Law, W., Ozbilgili, E., & Yarnoff, B. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2245465 · Cited by 3 · see citing works
Otunuga, O. M., & Yu, A. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.05.010 · Cited by 2 · see citing works
Ma, K. C., Surie, D., Dean, N. E., Paden, C. R., Thornburg, N. J., & Dawood, F. S. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag059 · Cited by 1 · see citing works
Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Fafard, J., Gilca, R., Talbot, D. C., Ouakki, M., Febriani, Y., et al. (2022) · medRxiv · doi:10.1101/2022.12.21.22283740 · Cited by 2 · see citing works
Akoury, N. A., Spinardi, J., Haridy, H., Moussa, M., Elshabrawi, M. A., Mendoza, C. F., Yang, J., Dodd, J., Kyaw, M. H., & Yarnoff, B. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2438757 · Cited by 1 · see citing works
Next-Generation Coronavirus Disease 2019 Vaccines
Stephenson, K. E. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.02.003 · Cited by 1 · see citing works
Roederer, A. L., Li, C. J., Lim, E., Cao, Y., Ronsard, L., Lingwood, D., Canaday, D. H., Gravenstein, S., & Balazs, A. B. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116954 · Cited by 1 · see citing works
Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant
Wang, H., Liu, L., & Wu, T. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-0991-0 · Cited by 1 · see citing works
Evaluation of mitigation policies against Omicron BA.5 in Japan: Testing, quarantine, and isolationPreprint
Chiba, A. (2022) · Research Square · doi:10.21203/rs.3.rs-2318818/v1
Milota, T., Smetanová, J., Skotnicová, A., Rataj, M., Lašťovička, J., Zelená, H., Bartůňková, J., & Kalina, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3307104/v1
Akoury, N. A., Spinardi, J., Haridy, H., -Osman, N. M., Mphahlele, N., Mendoza, C. F., Yang, J., Aruffo, E., Kyaw, M. H., & Yarnoff, B. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2396091
Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023
Stouten, V., Evercooren, I. V., Vernemmen, C., Braeye, T., Catteau, L., Roelants, M., Billuart, M., Lamot, T., Sierra, N. B., Hammami, N., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127290
Thakkar, K. B., Kyaw, M. H., Surendran, S., Chirila, I., Mendoza, C. F., Husin, M., Tok, P. S. K., Jayaraj, V. J., Sivasampu, S., Dodd, J., et al. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00329-8
Dehnen, D., Botzenhardt, S., Giagkou, E., Enders, K., Hoeter, K., Simon, P. D., & Neuberger, E. W. I. (2025) · Virology Journal · doi:10.1186/s12985-025-03016-x
Thakkar, K., Kyaw, M. H., Chirila, I., Mendoza, C. F., Dodd, J., & Yarnoff, B. (2026) · Pulmonary Therapy · doi:10.1007/s41030-025-00340-z
Thakkar, K., Thamaree, R., Kyaw, M. H., Chirila, I., Mendoza, C. F., Dodd, J., Yarnoff, B., & Kiertiburanakul, S. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00358-x
BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years
Tartof, S. Y., Ahi, T., Frankland, T. B., Slezak, J. M., Zamparo, J. M., Ackerson, B. K., & Puzniak, L. (2026) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piag029
Self-citation
- Authors
- Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Ackerson, B. K., Takhar, H., Ogun, O. A., Simmons, S., Zamparo, J. M., Jodar, L., & McLaughlin, J. M.
- Affiliations
- Kaiser Permanente (US)
- Pfizer (United States) (US)
- Corresponding author
- Tartof, Sara Y
- ORCID
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 22
- Issue
- 12
- Pages
- 1663-1665
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC9597567
- OpenAlex
- W4307399948
- Cited by
- 66
- References
- 4
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 10 · 2023: 36 · 2022: 7
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-03-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer Inc Boulder
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, Omicron variant, BA.4, BA.5, vaccine effectiveness, spike protein mutations, L452R, receptor binding domain, immune evasion, neutralizing antibodies, COVID-19 pandemic
- MeSH terms
- COVID-19, SARS-CoV-2, Vaccine Efficacy, BNT162 Vaccine, Antibodies, Viral, Humans, Neutralization Tests, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
